Tempus AI (TEM) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Tempus AI (NASDAQ: TEM) recently:

• 11/11/2025 – Tempus AI had its price target raised by analysts at Morgan Stanley from $68.00 to $80.00. They now have an “overweight” rating on the stock.
• 11/11/2025 – Tempus AI had its price target lowered by analysts at Piper Sandler from $105.00 to $80.00. They now have a “neutral” rating on the stock.
• 11/7/2025 – Tempus AI had its price target lowered by analysts at HC Wainwright from $98.00 to $89.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Tempus AI had its price target lowered by analysts at Canaccord Genuity Group Inc. from $110.00 to $95.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Tempus AI had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $96.00 price target on the stock.
• 11/5/2025 – Tempus AI had its price target raised by analysts at Needham & Company LLC from $70.00 to $100.00. They now have a “buy” rating on the stock.
• 10/22/2025 – Tempus AI had its price target raised by analysts at Piper Sandler from $70.00 to $105.00. They now have a “neutral” rating on the stock.
• 10/22/2025 – Tempus AI had its price target raised by analysts at BTIG Research from $85.00 to $96.00. They now have a “buy” rating on the stock.
• 10/21/2025 – Tempus AI was downgraded by analysts at Cowen Inc from a “buy” rating to a “hold” rating.
• 10/21/2025 – Tempus AI was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating. They now have a $88.00 price target on the stock.
• 10/20/2025 – Tempus AI is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $110.00 price target on the stock.
• 10/20/2025 – Tempus AI is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $110.00 price target on the stock.
• 10/8/2025 – Tempus AI had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Tempus AI had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/26/2025 – Tempus AI had its price target raised by analysts at Guggenheim from $80.00 to $95.00. They now have a “buy” rating on the stock.

Insider Activity at Tempus AI

In other news, COO Ryan Fukushima sold 5,000 shares of the business’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $92.32, for a total transaction of $461,600.00. Following the sale, the chief operating officer owned 130,000 shares in the company, valued at approximately $12,001,600. The trade was a 3.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 332,500 shares of Tempus AI stock in a transaction dated Thursday, September 25th. The shares were sold at an average price of $76.56, for a total transaction of $25,456,200.00. Following the transaction, the chief executive officer directly owned 9,141,032 shares of the company’s stock, valued at approximately $699,837,409.92. This trade represents a 3.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,007,870 shares of company stock worth $80,663,575 over the last 90 days. 26.27% of the stock is owned by company insiders.

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.